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Limited data are available on Chryseobacterium spp. leading to an evaluation of the patient demographics
and susceptibility patterns for Chryseobacterium spp. collected in the first 5 years of the SENTRY Antimicrobial
Surveillance Program (1997 to 2001). Fifty isolates (24 Chryseobacterium meningosepticum, 20 Chryseobacterium
indologenes, two Chryseobacterium gleum, and 4 Chryseobacterium spp. isolates) were collected. The highest
Chryseobacterium prevalence was detected among the elderly. The most active antimicrobials were the newer
quinolones (garenoxacin, gatifloxacin, and levofloxacin, each with a MIC at which 90 percent of the isolates are
inhibited [MIC90] of 1 g/ml and 98.0% susceptibility) followed by rifampin (MIC90, 2 g/ml and 85.7%
susceptibility). Trimethoprim-sulfamethoxazole, ciprofloxacin, and piperacillin-tazobactam also showed rea-
sonable activity; vancomycin showed poor potency.
Ubiquitous in nature, Chryseobacterium species are found
primarily in soil and water. Environmental studies have re-
vealed that these organisms can survive in chlorine-treated
municipal water supplies, often colonizing sink basins and taps
and creating potential reservoirs for infections inside hospital
environments. Colonization of patients via contaminated med-
ical devices involving fluids (respirators, intubation tubes, mist
tents, humidifiers, incubators for newborns, ice chests, sy-
ringes, etc.) has been documented (8, 12). Contaminated sur-
gically implanted devices such as intravascular catheters and
prosthetic valves have also been reported (18). In other clinical
settings, chryseobacteria have been described as etiological
agents of meningitis, bacteremia, pneumonia, endocarditis, in-
fections of skin and soft tissue, ocular infections, and other
infections (6). Primarily opportunistic pathogens, they infect
mainly newborns and immunocompromised hosts from all age
groups.
Chryseobacterium meningosepticum is the most pathogenic
member of the genus. As an agent of neonatal meningitis, it
reportedly demonstrates mortality rates of up to 57% and
produces severe postinfection sequelae including hydrocepha-
lus, deafness, and developmental delay. C. meningosepticum is
involved to a lesser extent in cases of pneumonia and bacterial
sepsis in neonates and adults (6, 23).
Antimicrobial susceptibility data on Chryseobacterium spp.
remain very limited, since this pathogen has been rarely iso-
lated from clinical specimens. In addition, results of suscepti-
bility testing vary when different methods are used. Results
from disk diffusion methods may not be reliable, so broth ref-
erence quality microdilution tests should be performed when
possible (1, 9).
Increasing concerns over the possibility of disseminating
plasmid-mediated carbapenem-hydrolyzing enzymes has led
researchers to characterize the natural reservoir of chromo-
somally linked metallo--lactamases (MLs) found in Chryseo-
bacterium strains (3, 5). Multiple heterogeneous carbapenem-
hydrolyzing enzymes have been reported in a single strain of
C. meningosepticum. Investigations have also detected syner-
gistic effects between cephalosporins and clavulanic acid, add-
ing Ambler class A extended-spectrum -lactamases to the
growing list of resistance mechanisms found in chryseobacteria
(4, 21).
Chryseobacterium spp. are known to exhibit resistance to
aminoglycosides, tetracyclines, chloramphenicol, erythromy-
cin, clindamycin, and teicoplanin (1, 6, 14). However, some
fluoroquinolones have shown favorable results (9, 25). Mino-
cycline has also shown good in vitro activity, while susceptibil-
ity to doxycycline and trimethoprim-sulfamethoxazole appears
variable. Rifampin is usually active in vitro and has been used
as part of a combination therapy to clear persistent infection
(11). Vancomycin alone or in combination with other agents,
including rifampin, has in the past been successful in the treat-
ment of meningitis in infants (20). However, the usefulness of
vancomycin against Chryseobacterium spp. infections has more
recently been questioned (6, 9). Thus, there is no optimal
regimen for the treatment of Chryseobacterium spp. infections
and antimicrobial therapy should be based on MIC from prop-
erly performed susceptibility tests.
The SENTRY Antimicrobial Surveillance Program is a
world-wide study monitoring the susceptibility and resistance
patterns of bacterial and fungal pathogens. This investigation
was conducted by using results from over 119 sentinel hospitals
and laboratories in North America, Latin America, Europe,
and the Asia-Pacific region from the initial 5 years of the
program (1997 to 2001). During this time period, over 155,811
clinical isolates were collected from several sites of infections,
including bloodstream, the lower respiratory tract, skin and
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soft tissue, and the urinary tract. All Chryseobacterium spp.
isolates collected during this period were evaluated. Fifty iso-
lates unique to a given patient were identified and selected for
detailed characterization and additional antimicrobial suscep-
tibility testing.
Individual strains came from hospitalized patients in the
Asia-Pacific region (16 strains from 7 centers), Europe (5
strains from 5 centers), Latin America (14 strains from 6 cen-
ters), and North America (15 strains from 15 centers). Each
strain was tested against 47 antimicrobials, of which only se-
lected agents were used for comparison of activity. Manufac-
turers for each agent supplied standard compounds that were
placed in dry-form, validated microdilution panels (Trek Di-
agnostic Systems Inc., Cleveland, Ohio). All organisms were
tested by broth microdilution methodology as specified by the
NCCLS (16). Interpretation of quantitative MIC results was in
accordance with NCCLS (16, 17) criteria. Selected gram-pos-
itive-active drugs were tested against Chryseobacterium spp.
isolates, and the results were interpreted according to break-
points approved for Staphylococcus or Enterococcus species by
the NCCLS (17).
Multiple isolates of the same species isolated by the same
medical center were selected for molecular typing. These iso-
lates were characterized by macrorestriction analysis of chro-
mosomal DNA by using pulsed-field gel electrophoresis
(PFGE) as previously described (19, 24). Meropenem hydro-
lysis was evaluated for 21 randomly selected strains (11 C.
indologenes and 10 C. meningosepticum isolates) by UV spec-
trophotometric assays (Pharmacia LKB Ultrospec II) in 1-cm
light path cuvettes with readings recorded at 2-s intervals for 2
min at a wavelength of optimal absorbance (loss of substrate at
298 nm). The ability to induce MLs was assessed by challeng-
ing mid-log growth cells with cefoxitin at 0.25 g/ml for 2 h
(26). The cells were harvested by centrifugation (12,000  g),
washed in the aforementioned buffer, and ribolysed. The ribo-
lysed cells were centrifuged at 12,000  g to remove cellular
debris. The activities of the enzymes were converted to a spe-
cific activity (micromolar substrate hydrolyzed/minute/milli-
gram of protein) using 2,500 as the extinction coefficient for
meropenem as previously described (2).
The 50 isolates were collected from 33 medical centers in 16
countries. Only three medical centers sent multiple isolates of
the same species. Chryseobacterium spp. represented only
0.27% (50 of 18,569) of the processed nonfermentative gram-
negative bacilli and 0.03% (50 of 155,811) of all bacterial
isolates collected by the SENTRY Program during the 5-year
period evaluated (1997 to 2001). In addition, Chryseobacterium
spp. represented only 0.10% of respiratory tract isolates and
0.03% of bloodstream infection isolates. The low frequency of
this pathogen as a cause of infection is probably related to its
reduced degree of pathogenicity. Some studies have shown
that Chryseobacterium can be rapidly cleared by the immune
system when introduced into the bloodstream or respiratory
tract of a healthy animal or human host (6, 8, 22).
The most frequently isolated species was C. meningosepti-
cum (24 isolates [48.0%]), followed by C. indologenes (20 iso-
lates [40%]) and C. gleum (2 isolates [4.0%]). Four isolates
(8.0%) could not be identified to the species level. All isolates
were from hospitalized patients, and the vast majority was
recovered from either lower respiratory tract (26 isolates
[52.0%]) or blood cultures (23 isolates [46.0%]). The fre-
quency of Chryseobacterium among respiratory tract specimens
(0.10%; 26 of 25,657 specimens evaluated) was threefold high-
er than among positive blood cultures (0.03%; 23 of 74,236).
Among isolates from bloodstream infections, 52.2% were C.
meningosepticum and 30.4% were C. indologenes. Conversely,
one-half of the isolates from the respiratory tract were C. in-
dologenes and 42.3% were C. meningosepticum. One isolate
(C. meningosepticum) was recovered from skin and/or soft tis-
sue infection. The highest frequency of Chryseobacterium spp.
infection occurred among the elderly (65 years old; 0.045%)
and the lowest frequency occurred among children5 years of
age (0.016%).
The quinolones showed the highest potency and spectrum of
activity against the overall collection of Chryseobacterium spp.
Garenoxacin was the most active quinolone (MIC50, 0.12 g/
ml; MIC90, 1 g/ml), and this new desfluoro compound inhib-
ited 98.0% of isolates at the proposed susceptible breakpoint
for other nonfermentative gram-negative bacilli (2 g/ml) (13).
Gatifloxacin (MIC50, 0.25 g/ml) and levofloxacin (MIC50, 0.5
g/ml) also inhibited 98.0% of the isolates at susceptible break-
points (17), and the rate of susceptibility to ciprofloxacin
(MIC50, 0.5 g/ml) was significantly lower (80.0% overall).
Trimethoprim-sulfamethoxazole showed reasonable activity
(87.8% susceptibility overall). Among the -lactams, the most
active agents overall were piperacillin-tazobactam (MIC50, 4
g/ml; 80.0% susceptibility), piperacillin (MIC50, 8 g/ml;
74.0% susceptibility), and cefepime (MIC50, 8 g/ml; 62.0%
susceptibility). The carbapenems (6 to 12% susceptible) and
the aminoglycosides (8 to 14% susceptible) exhibited poor
activity against these pathogens. ML activity was demon-
strated for all isolates evaluated. Activity ranged from 381 to
788 (average 529) mol/min/mg of protein.
Many studies have shown that vancomycin has marginal in
vitro activity against Chryseobacterium spp. isolates. In addi-
tion, some reports have documented the successful use of
vancomycin to treat C. meningosepticum infections, and this
antimicrobial agent has been recommended as a therapeutic
choice (7, 8, 10). We tested vancomycin and several other
antimicrobial agents used to treat gram-positive infections, and
all of these compounds showed poor activity against the con-
temporary Chryseobacterium spp. isolates tested. For the vast
majority of strains (87.8%) the vancomycin MIC was interme-
diate (8 to 16 g/ml). Rifampin was active against the majority
of strains (85.7% susceptibility overall) and can be used in
combination to treat severe invasive infections (10, 11).
C. meningosepticum showed slightly lower susceptibility rates
to the -lactams (71.0% susceptibility to piperacillin-tazobac-
tam) and to trimethoprim-sulfamethoxazole (79.2%) when
compared to C. indologenes (90.0 and 95.0% susceptibility to
piperacillin-tazobactam and trimethoprim-sulfamethoxazole,
respectively). On the other hand, these two species had similar
rates of susceptibility to fluoroquinolones and other antimicro-
bial agents (Table 1).
Interestingly, isolates from the Asia-Pacific region showed
higher rates of resistance to the -lactams (Table 2). The rate
of susceptibility to piperacillin-tazobactam was only 50.0% in
the Asia-Pacific region (16 isolates) compared to 100% in
North America (15 isolates) and Europe (5 isolates) and 85.7%
in Latin America (14 isolates). This higher rate of resistance
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may be related to the higher proportion of C. meningosepticum
isolated in this region, since this species has shown higher rates
of resistance than C. indologenes, especially for -lactams and
trimethoprim-sulfamethoxazole (Table 1). Susceptibility rates
did not vary greatly among regions for other classes of antimi-
crobial agents (Table 2).
Thirteen strains (five C. indologenes and eight C. meningo-
septicum isolates) from three medical centers (Brazil, China,
and Hong Kong) were characterized by PFGE. Among C.
indologenes, three isolates from a Brazilian center had identical
PFGE patterns. Two C. meningosepticum isolates from the
same Brazilian medical center also shared a unique PFGE
pattern. These isolates were collected from elderly patients
(ages 66 to 90 years) with nosocomial pneumonia hospitalized
in intensive care units (ICU). All other tested isolates had
distinct chromosomal DNA profiles. The finding of two small
epidemic clusters involving elderly patients hospitalized in the
ICU with lower respiratory tract infections raises concern for
the possible occurrence of outbreaks in this patient population.
Chryseobacterium spp. colonization in patients admitted to a
respiratory-surgical ICU was reported more than two decades
ago, and it was linked to the municipal water supply (8). In
addition, its unusual resistance to antimicrobial agents directed
to gram-negative bacteria allows for favorable environmental
competition and subsequent colonization. Once patients be-
come colonized, organisms can be transmitted to noncolonized
patients primarily by hand carriage (8, 15).
In summary, the results of the evaluation of a world-wide
TABLE 1. Spectrum of selected antimicrobial agents against the most frequently isolated species
Antimicrobial agenta
C. meningosepticum (n  24) C. indologenes (n  20)
MIC50 MIC90 % Susceptible % Resistant MIC50 MIC90 % Susceptible % Resistant
Gatifloxacin 0.5 2 100.0 0.0 0.25 1 95.0 0.0
Garenoxacinb 0.12 1 100.0 0.0 0.12 2 95.0 0.0
Levofloxacin 0.5 2 95.8 4.2 0.5 1 100.0 0.0
Ciprofloxacin 1 2 70.9 16.7 0.5 2 85.0 10.0
Trimethoprim-sulfamethoxazole 2 2 79.2 20.8 0.5 2 95.0 5.0
Piperacillin-tazobactam 8 64 71.0 4.2 4 32 90.0 5.0
Piperacillin 8 128 62.4 29.2 4 32 85.0 10.0
Ticarcillin-clavulanate 128 128 0.0 58.3 128 128 5.0 90.0
Cefepime 16 16 37.6 33.0 0.5 16 85.0 15.0
Ceftazidime 16 16 4.2 91.7 4 16 85.0 15.0
Ceftriaxone 32 32 4.2 37.5 16 32 35.0 15.0
Imipenem 8 8 0.0 95.8 8 8 15.0 85.0
Meropenem 8 8 0.0 91.7 8 8 10.0 90.0
Amikacin 32 32 4.2 62.5 8 8 15.0 20.0
Gentamicin 8 8 8.3 91.7 8 8 5.0 95.0
Tobramycin 16 16 0.0 100.0 16 16 0.0 100.0
Chloramphenicol 16 16 4.2 79.2 16 16 5.0 85.0
Linezolidc 8 8 8.3 91.7 8 8 5.0 95.0
Teicoplaninc 16 16 20.9 33.3 16 16 5.0 60.0
Vancomycinc 16 16 4.2 4.2 16 16 0.0 20.0
Rifampinc 0.5 2 87.5 0.0 0.5 2 85.0 0.0
a NCCLS MIC breakpoints for non-Enterobacteriaceae were categorically applied to Chryseobacterium spp.
b A susceptibility breakpoint of 2 g/ml was applied (13).
c The NCCLS MIC breakpoint for Staphylococcus spp. was applied (17).
TABLE 2. In vitro activities of selected antimicrobials against Chryseobacterium spp. according to SENTRY region
Antimicrobial agenta
Asia-West Pacific (n  16) Europe (n  5) Latin America (n  14) North America (n  15)
% Susceptible % Resistant % Susceptible % Resistant % Susceptible % Resistant % Susceptible % Resistant
Gatifloxacin 100.0 0.0 100.0 0.0 92.9 0.0 100.0 0.0
Garenoxacinb 100.0 0.0 100.0 0.0 92.9 0.0 100.0 0.0
Levofloxacin 100.0 0.0 100.0 0.0 100.0 0.0 93.3 6.7
Ciprofloxacin 68.8 12.5 100.0 0.0 85.7 7.1 80.0 20.0
Trimethoprim-sulfamethoxazole 81.3 18.7 80.0 20.0d 85.7 14.3 93.3 6.7
Piperacillin-tazobactam 50.0 6.3 100.0 0.0 85.7 7.1 100.0 0.0
Piperacillin 37.5 50.1 100.0 0.0 85.7 14.3 93.3 0.0
Cefepime 18.8 62.5 100.0 0.0 64.3 14.3 93.3 0.0
Ceftazidime 12.5 87.5 100.0 0.0 57.1 42.9 53.3 40.0
Imipenem 0.0 100.0 20.0 80.0 14.3 85.7 20.0 73.3
Amikacin 6.3 81.2 20.0 0.0 14.3 28.6 20.0 26.7
Rifampinc 93.8 0.0 75.0 0.0 85.7 0.0 80.0 0.0
a NCCLS MIC breakpoints for non-Enterobacteriaceae were categorically applied to Chryseobacterium spp. (17).
b A susceptibility breakpoint of 2 g/ml was applied (13).
c NCCLS MIC breakpoints for Staphylococcus spp. were applied (17).
d A C. gleum isolate had an MIC 1/19 g/ml and was not available for retesting.
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collection of unique Chryseobacterium strains indicate that (i)
the newer quinolones (garenoxacin, gatifloxacin, and levofloxa-
cin) may represent the most appropriate antimicrobial agents
to treat infections caused by this pathogen, (ii) vancomycin and
other anti-gram-positive antimicrobial agents may not repre-
sent satisfactory therapeutic options for Chryseobacterium in-
fections, (iii) the production of metallo--lactamase seems to
be constitutive among Chryseobacterium spp., and (iv) epi-
demic clusters may occur among elderly patients hospitalized
in ICUs. Extensive world-wide surveillance programs, such as
the SENTRY Program, are extremely important to guide em-
pirical antimicrobial therapy and clinical context of rarely iso-
lated pathogens.
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